SRSD216
Lipoprotein(a) (Lp(a)) Reduction
Phase 1/2aActive
Key Facts
About Sirius Therapeutics
Sirius Therapeutics is an innovative, privately-held biotech advancing a pipeline of siRNA therapies targeting major chronic diseases, with lead programs in Phase 2 and Phase 1/2a trials. The company has established a strong operational footprint in both the US and China, securing funding from top-tier investors like OrbiMed and forging a strategic collaboration with CRISPR Therapeutics. Its strategy is built on three 'mega-blockbuster' franchises in cardiovascular and metabolic diseases, supported by its proprietary PEPR siRNA technology platform.
View full company profile